The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...

Dr Reddy's Laboratories Ltd.'s formulations manufacturing facility was given "Form 483" with seven observations from the ...

US stocks start up on earnings reports and before a consumer sentiment survey that'll show if consumers are feeling the weight of Trump's tariffs.